Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$3.76B+22.89%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Scott Andrew Smith
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 30,000
- Beta
- 0.86
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.12
Financials
Revenue
$3.76B+22.9%Net Income
$-118.80MEBITDA
$729.00M+175.1%Free Cash Flow
$329.00M-69.6%EPS (diluted)
$-0.10Shares Outstanding (diluted)
1.16B+122.2%Operating Expenses
$1.38BCash & Debt
$1.51BReturn of Capital
$289.80MRevenue by Segment (annual)
$14.25BDividend per Share
$0.12Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.30B | $-3.51B | $-3.00 |
| 2024 | $14.74B | $-634.20M | $-0.53 |
| 2023 | $15.43B | $54.70M | $0.05 |
| 2022 | $16.26B | $2.08B | $1.71 |
| 2021 | $17.89B | $-1.27B | $-1.05 |
| 2020 | $11.95B | $-669.90M | $-1.11 |
| 2019 | $11.50B | $16.80M | $0.03 |
| 2018 | $11.43B | $352.50M | $0.69 |
| 2017 | $11.91B | $696.00M | $1.30 |
| 2016 | $11.08B | $480.00M | $0.94 |
| 2015 | $9.43B | $847.60M | $1.80 |
| 2014 | $7.72B | $929.40M | $2.49 |
| 2013 | $6.91B | $623.70M | $1.63 |
| 2012 | $6.80B | $640.85M | $1.54 |
Valuation
VTRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-85.71%Social Signal Score
Mentions (17)
- Newsprnewswire.com·8d ago·Negative
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FD…
View source ↗ - News (RSS)seekingalpha·12d ago·Neutral
Viatris: Improved Confidence Drives M&A Action Again
View source ↗ - Newszacks.com·15d ago·Positive
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
View source ↗ - News (RSS)seekingalpha·15d ago·Neutral
Viatris To Acquire Pacira BioSciences: What Investors Should Know
View source ↗ - News (RSS)wsj·16d ago·Negative
Viatris to Buy Pacira BioSciences for $1.65 Billion Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company’s medicines portfolio.
View source ↗ - Newswsj.com·16d ago·Negative
Viatris to Buy Pacira BioSciences for $1.65 Billion Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
View source ↗ - Newsprnewswire.com·16d ago·Negative
…ned and Balanced Capital Allocation Strategy and Preserves Financial Flexibility PITTSBURGH and BRISBANE, Calif. , Oct. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, today announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, represen…
View source ↗ - Newszacks.com·19d ago·Positive
Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsprnewswire.com·25d ago·Positive
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year PITTSBURGH, Sept. 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth consecutive year.
View source ↗ - News (RSS)seekingalpha·28d ago·Neutral
Viatris sues Novo Nordisk, seeks to market generic Wegovy
View source ↗ - News (RSS)investing·28d ago·Neutral
Viatris sues Novo Nordisk over generic Wegovy patent dispute
View source ↗ - News (Marketaux)gurufocus.com·30d ago·Positive
VTRS Looks 49.7% Overvalued on GF Value™ On September 23, 2026, Oppenheimer initi[+305 characters]
View source ↗ - News (RSS)investing·38d ago·Negative
Viatris receives Japan approval for sleep disorder drug Wakix
View source ↗ - Newsprnewswire.com·38d ago·Neutral
…proval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for …
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive Viatris' Q2 showed better earnings quality, with adjusted net income and EPS up 11% while free cash flow doubled year-over-year. Deleveraging remains on track, while buybacks and dividends demonstrate that stronger cash generation is already supporting shareholder returns. Pipeline progress and new-product approvals provide additional growth optionality beyond the mature portfolio, with key Phase 3 assets approa…
View source ↗ - News (Marketaux)economictimes.indiatimes.com·46d ago·Neutral
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid (BBB-/Stable/--) and Viatris <e[+99 characters]
View source ↗ - Newsproactiveinvestors.co.uk·57d ago·Positive
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential upside of 318% from current share price of about 5.5 pence.
View source ↗
Earnings
Thu, Nov 5(in 11 days)
Consensus estimate $0.64 per share
Typical surprise +7.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.69 vs $0.60beat
- Thu, May 7$0.59 vs $0.50beat
- Thu, Feb 26$0.57 vs $0.53beat
- Thu, Nov 6$0.67 vs $0.62beat
- Thu, Aug 7$0.62 vs $0.56beat
- Thu, May 8$0.50 vs $0.49beat
Estimates and results for VTRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VTRS officers and directors.
- Bought
- $5k
- Sold
- $1.1m
2 trades
2 trades
- Campbell Paulsold
- Campbell Paulsold
- Simmons David Sbought
- Simmons David Sbought
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 7, 2025 (7d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 7, 2022 (8d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Sep 15, 2022 (45d later)Sell$1,001 - $15,000
- Carol Devine Millerhouse · WV03 · disclosed Sep 2, 2022 (547d later)Sell$1,001 - $15,000
- Earl Blumenauerhouse · OR03 · disclosed Apr 1, 2022 (36d later)Buy$1,001 - $15,000
- Earl Blumenauerhouse · OR03 · disclosed Apr 1, 2022 (18d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Feb 14, 2022 (32d later)Sell$1,001 - $15,000
- Debbie Dingellhouse · MI12 · disclosed Jun 29, 2021 (11d later)Sell$1,001 - $15,000
- Scott Franklinhouse · FL15 · disclosed Jun 8, 2021 (19d later)Sell$15,001 - $50,000
- Scott Franklinhouse · FL15 · disclosed Jun 8, 2021 (19d later)Sell$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.